METHODS: In this double-blind trial, we enrolled 1961 adults with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or greater (27 in persons with 1 weight-related coexisting condition), who did not have diabetes, and randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention
Additionally, many individuals report a reduced appetite and a change in eating habits, such as feeling full faster and a decrease in cravings for unhealthy foods, which contribute to a sustainable health-oriented lifestyle
Signs Your Compounded Semaglutide Has Degraded and Should Be Discarded Visual changes indicate degradation: discoloration, cloudiness, or visible particles in the solution warrant immediate discard
doi: 10.1371/journal.pone.0226303 171 ArodaVREdelsteinSLGoldbergRBKnowlerWCMarcovinaSMOrchardTJet al